Table 1 Participant demographics and baseline characteristics

From: A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE

Characteristics

n (%)

Median age (range)

60 years (32–86)

Sex

 Female

29 (62)

 Male

18 (38)

ECOG performance status

 0

23 (49)

 1

22 (47)

 2

2 (4)

Smoking status

 Current smoker

1 (2)

 Former smoker

15 (32)

 Never smoker

31 (66)

Ethnicity

 Asian

19 (40)

 Non-Asian

28 (60)

EGFR driver mutation

 Exon 19 deletion

30 (64)

 Exon 21 L858R substitution

16 (34)

 Exon 21 L861Q mutation

1 (2)

 Exon 20 S768I mutation

1 (2)

Baseline T790M detection

 Plasma

26 (55)

 Tissue

21 (45)

Sites of metastatic disease

 Brain

14 (21)

 Leptomeningeal

1 (2)

 Liver

9 (19)

No of prior systemic therapy

 1

44 (94)

 2

3 (6)

Back to article page